Labroots

Beyond CRISPR Basics: Molecular Biology Innovations in Cell Engineering

Beginning with a brief historical overview of CRISPR, we will trace its evolution to the current state of gene engineering, highlighting its pivotal role in reshaping the landscape of molecular ...

Sharper gene scissors for the biotechnology toolbox

The goal of gene therapy is to permanently cure hereditary diseases. One of the most promising technologies for this is the ...
Scientific American

FDA Approves First CRISPR Gene Editing Treatment for Sickle Cell Disease

CRISPR, the gene-editing technology that has revolutionized biological research, is finally available as a medical treatment with regulatory approval. On December 8 the U.S. Food and Drug ...
FiercePharma

Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia

Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval comes ...

CRISPR Gene Editing Market To Hit $12.78B By 2033, Kits & Reagents 60.5% Share, Cas9 Drives Innovation

CRISPR Gene Editing Market To Hit $12.78B By 2033, Kits & Reagents 60.5% Share, Cas9 Drives Innovation. EINPresswire/ -- CRISPR Gene Editing: A Technological Overview CRISPR gene editing has ...
The Motley Fool

Where Will CRISPR Therapeutics Be in 5 Years?

CRISPR Therapeutics now has an approved product in its portfolio in Casgevy. The treatment has the potential to be a game changer for the company's business. Even with more treatments in its portfolio ...
FierceBiotech

Vertex cuts ties to CRISPR Therapeutics’ type 1 diabetes stem cell therapy

Vertex is severing one of its ties to CRISPR Therapeutics. The big biotech has chosen to opt out of the diabetes gene-edited stem cell therapy it gained through the acquisition of ViaCyte, leaving ...